Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M)

BACKGROUND: Calmangafodipir (CaM, PledOx) demonstrated efficacy in preventing patient-reported chemotherapy-induced peripheral neuropathy (CIPN) in a randomized phase 2 study in patients with metastatic colorectal cancer. The Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy (POLAR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeiffer, Per, Lustberg, Maryam, Näsström, Jacques, Carlsson, Stefan, Persson, Anders, Nagahama, Fumiko, Cavaletti, Guido, Glimelius, Bengt, Muro, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678401/
https://www.ncbi.nlm.nih.gov/pubmed/36308441
http://dx.doi.org/10.1093/jncics/pkac075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678401/
https://www.ncbi.nlm.nih.gov/pubmed/36308441
http://dx.doi.org/10.1093/jncics/pkac075

Ejemplares similares